| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/10/2004 | WO2004075856A2 Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases |
| 09/10/2004 | WO2004075852A2 Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions |
| 09/10/2004 | WO2004054565A8 Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
| 09/10/2004 | WO2004052390B1 Methods and compositions for treating polycystic ovary syndrome |
| 09/10/2004 | WO2004043392B1 Mucin synthesis inhibitors |
| 09/10/2004 | WO2004039409A3 Composition comprising activators of ik potassium channels and calcineurin antagonists and use thereof |
| 09/10/2004 | WO2004028451A3 β-HYDROXYPHENYLALKYLAMINES AND THEIR USE FOR TREATING GLAUCOMA |
| 09/10/2004 | WO2004019885A3 Fast dissolving film delivery of nucleotides that inhibit the unpleasant taste of bitter tasting medications |
| 09/10/2004 | WO2004014352A3 Methods for treating carbonic anhydrase mediated disorders |
| 09/10/2004 | WO2003106970A3 P27 prevents cellular migration |
| 09/10/2004 | WO2003101281A3 Method for reducing obstructive hydrocephalus |
| 09/10/2004 | WO2003090671A3 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance |
| 09/10/2004 | WO2003076579A3 Cancer-linked gene as target for chemotherapy |
| 09/10/2004 | WO2003070191A3 Tamper-resistant transdermal opioid delivery devices |
| 09/10/2004 | WO2003045230A3 Novel compositions and methods for cancer |
| 09/10/2004 | WO2003038129A3 Methods for assessing and treating leukemia |
| 09/10/2004 | WO2003003979A3 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 09/10/2004 | WO2002098890A3 MARKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 09/10/2004 | WO2002097053A3 Small molecule antagonists of bcl2 family proteins |
| 09/10/2004 | WO2002094780A3 Kinases and phosphatases |
| 09/10/2004 | WO2002092840A3 Agents that regulate apoptosis |
| 09/10/2004 | WO2002064085A3 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| 09/10/2004 | CA2517007A1 Therapeutic malonic acid/acetic acid c60 tri-adducts of buckminsterfullerene and methods related thereto |
| 09/10/2004 | CA2516730A1 Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases |
| 09/10/2004 | CA2516579A1 Method of detecting onset risk of encephalitis or encephalopathy |
| 09/10/2004 | CA2515210A1 Combined use of ribavirin and interferon beta in demyelinating diseases |
| 09/09/2004 | US20040177388 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 09/09/2004 | US20040176598 Azaindoles coupled with piperidine or piperazine and linker to cyclic group |
| 09/09/2004 | US20040176473 Methods for delivering compounds into a cell |
| 09/09/2004 | US20040176470 suppressing, inhibiting, or reducing the incidence of pre-malignant lesions of prostate cancer |
| 09/09/2004 | US20040176469 Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy |
| 09/09/2004 | US20040176466 an effective amount of atomoxetine in combination with an inhibitor of Cytochrome P450s for patients who are extensive metabolizers; administering to a patient who has previously not responded to attention-deficit/hyperactivity disorder treatment |
| 09/09/2004 | US20040176461 Sulfonyl-amino or carbonyl-amino derivatives; osteoporosis bone disorders; therapeutic drug or kits including anti-resorptive agents, anabolic agents; |
| 09/09/2004 | US20040176456 Method of treatment for sexual dysfunction |
| 09/09/2004 | US20040176442 Potassium taurate bicarbonate and ascorbate |
| 09/09/2004 | US20040176439 coadministration of agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F) |
| 09/09/2004 | US20040176428 treatment of Type 2 diabetes mellitus, obesity and lipid disorders; coadministration with HMG CoA reductase inhibitors |
| 09/09/2004 | US20040176423 HMG-CoA reductase inhibitor with a prostaglandin agonist; treating cartilage defects or disorders or promoting wound healing |
| 09/09/2004 | US20040176419 particularly chronic obstructive pulmonary disease (COPD), asthma or a related pulmonary disease such as chronic bronchitis or allergic rhinitis |
| 09/09/2004 | US20040176414 principle metabolite of cisapride; has both 5-HT3 antagonistic and 5-HT4 agonistic; devoid of central nervous system effects; separating racemic mixture by liquid chromatography over a chiral stationary phase |
| 09/09/2004 | US20040176404 Methods and reagents for treating or preventing atherosclerosis and diseases associated therewith |
| 09/09/2004 | US20040176403 Methods for treating multidrug resistance |
| 09/09/2004 | US20040176397 (Oxo-Pyrazolo[1,5a]pyrimidin-2-yl)Alkyl-Carboxamides |
| 09/09/2004 | US20040176396 anti-protoazoal; poultry feed; therapy for cytokine mediated disease i.e. osteoarthritis, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, bone resorption diseases, reperfusion injury, graft v. host rejection |
| 09/09/2004 | US20040176393 2-(4'-bromobiphenyl-4-sulfonylamino)-3-methylbutyric acid with atorvastatin |
| 09/09/2004 | US20040176378 for the treatment or prevention of ischemic-mediated central nervous system damage, including ischemic stroke |
| 09/09/2004 | US20040176373 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and an agent used in the treatment of the cardiac conditions associated with diabetes mellitus |
| 09/09/2004 | US20040176360 Administering taurolidine, taurultam, or a biologically active derivative to mammal to directly contact tumor cell at dosage sufficient to induce cell death by apoptosis; side effect reduction |
| 09/09/2004 | US20040176355 Melanin-concentrating hormone antagonists for eating disorder and diabetes treatment |
| 09/09/2004 | US20040176349 Antibacterial composition |
| 09/09/2004 | US20040176347 Synergistic mixture of astrocyte function-improving agent and tissue plasminogen activator thrombolytic agent |
| 09/09/2004 | US20040176345 Administering a quenching photosensitizer molecule for side effect reduction to retinal pigmented epithelium; age related macular degeneration |
| 09/09/2004 | US20040176343 Platinum amine glycine complex derivatives; antiproliferative and antitumor agents; side effect reduction; reversibly active; on and off |
| 09/09/2004 | US20040176341 Injectable sustained release delivery devices |
| 09/09/2004 | US20040176339 Antineoplastic combinations |
| 09/09/2004 | US20040176338 Pharmaceutical compositions based on anticholinergics and corticosteroids |
| 09/09/2004 | US20040176324 Derivatives of 4,7-ethanothiopyrano[3,4-c]pyrrole-1,3-(2H)-dione, 4,7-epoxy-1H-isoindole-1,3(2H)-dione, and/or 4,7-ethano-1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives; autoimmune diseases; anticarcinogenic agents |
| 09/09/2004 | US20040176318 Pretreating with lipophilic substituted saccharide |
| 09/09/2004 | US20040176315 Increasing efficacy while decreasing toxicity effects; combining multiple compounds modulating target molecule activity associated single nucleotide polymorphisms |
| 09/09/2004 | US20040176311 Synergistic impedance using two HMG-CoA reductase inhibitors; combination of isoprenoids, isoflavones and/or statins |
| 09/09/2004 | US20040176307 Method of regulating glucose metabolism, and reagents related thereto |
| 09/09/2004 | US20040176306 Compositions for raising uric acid levels and methods of using the same |
| 09/09/2004 | US20040176298 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors |
| 09/09/2004 | US20040176295 Method of promoting bone growth with hyaluronic acid and growth factors |
| 09/09/2004 | US20040176286 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions |
| 09/09/2004 | US20040176284 1,2-Dithio-5,8,11,14,17-pentaazocycloeicosane derivatives |
| 09/09/2004 | US20040176272 Uses of integrin alphavbeta3 antagonists |
| 09/09/2004 | US20040175773 Screening method based on siah-numb interaction |
| 09/09/2004 | US20040175767 for lightening or darkening the pigmentation of cells and tissue (skin) in cells/cell-free systems; for drug screening |
| 09/09/2004 | US20040175766 Human pyrimidine receptor |
| 09/09/2004 | US20040175748 Using alterations in cyclin dependent kinase activity to identify modulators which inhibit or potentiate cellular senescence; antiaging/anticancer agents; enzyme inhibitors |
| 09/09/2004 | US20040175740 Using proopiomelanocortin animal mutant to identify modulators of weight and pancreatic disorders |
| 09/09/2004 | US20040175730 Comprises nucleotide sequences coding polypeptide associated with vascular permeability or proliferation of endothelial cells for treating intestinal malabsorption syndrome |
| 09/09/2004 | US20040175700 Using phenotypic, genotypic, physiological and morphogenic variation profiles to diagnose and prognose genetic disorders; genomics |
| 09/09/2004 | US20040175443 Food supplement for increasing lean mass and strength |
| 09/09/2004 | US20040175442 Food supplement for increasing lean mass and strength |
| 09/09/2004 | US20040175433 using a viscous rather than a liquid footbath performs much better in preventing and combating hoof diseases; active ingredient and a colloid former |
| 09/09/2004 | US20040175432 Metallic comb incorporating copper salts |
| 09/09/2004 | US20040175420 at least one non-ionic or zwitterionic surfactant and dispersant; improves the efficacy and/or potency of the lipase inhibitor; inter-subject variability in efficacy and/or potency is reduced, as well as the frequency and intensity of side effects |
| 09/09/2004 | US20040175410 Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |
| 09/09/2004 | US20040175401 Drug delivery to the dermis mammal to improve systemic absorption |
| 09/09/2004 | US20040175382 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| 09/09/2004 | US20040175378 Monoclonal antibody 3G4, or an antigen-binding region or immunoconjugate thereof, produced by hybridoma ATCC PTA 4545; binds to phosphatidyl serine |
| 09/09/2004 | US20040175372 Inhibits rotavirus infection and other pathogenic microorganisms; viricides; preventing and treating diarrhea of mammals, livestock, and poultry |
| 09/09/2004 | US20040175365 Administering primer and boosting composition comprising source of one or more CD8+ T cell epitopes of melanoma from a source of non-replicating or replication-deficient recombinant poxvirus vector in the human |
| 09/09/2004 | US20040175362 Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| 09/09/2004 | US20040175349 Method of inhibiting hair growth |
| 09/09/2004 | US20040175342 Process of making and using composition containing oxidation-sensitive hydrophilic active principle and maleic anhydride copolymer |
| 09/08/2004 | EP1454525A1 NONHUMAN MODEL ANIMAL OF Th2-MEDIATED HYPERIMMUNE RESPONSE |
| 09/08/2004 | EP1454145A2 Method for the assessment and prognosis of sarcoidosis |
| 09/08/2004 | EP1454140A2 Diagnosis and treatment of atherosclerosis |
| 09/08/2004 | EP1454136A2 Methods and means for influencing intracellular communication and intracellular organelle transport |
| 09/08/2004 | EP1453913A2 Novel substituted alkane compounds and uses thereof |
| 09/08/2004 | EP1453856A1 Beta-amyloid binding factors and inhibitors thereof |
| 09/08/2004 | EP1453855A1 Antimicrobial bolisin peptides |
| 09/08/2004 | EP1453854A2 Human cdnas and proteins and uses thereof |
| 09/08/2004 | EP1453845A2 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
| 09/08/2004 | EP1453844A2 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents |
| 09/08/2004 | EP1453837A2 Targeted therapeutics and uses thereof |
| 09/08/2004 | EP1453835A2 Adenosine a 2a receptor antagonists |